Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

Deyali Chatterjee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3322-1163; OpenAlex author ID A5072825310. Sources: OpenAlex.

Their work

Papers
30 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
129
Papers, trials and grants by year

2012: 4 papers · 2013: 2 papers · 2014: 3 papers · 2015: 3 papers · 2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 3 papers · 2023: 4 papers · 2024: 2 papers

Papers 30

  1. Artificial Intelligence-based Segmentation of Residual Pancreatic Cancer in Resection Specimens Following Neoadjuvant Treatment (ISGPP-2): International Improv… Co-author DOI 10.1097/pas.0000000000002270↗
  2. The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Co-author DOI 10.3390/cancers16193312↗
  3. High-dimensional deconstruction of pancreatic cancer identifies tumor microenvironmental and developmental stemness features that predict survival. Co-author DOI 10.1038/s41698-023-00455-z↗
  4. Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Co-author DOI 10.1097/pas.0000000000002013↗
  5. Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy. Co-author DOI 10.3390/cancers15092608↗
  6. Comparative Analyses of the Clinicopathologic Features of Short-Term and Long-Term Survivors of Patients with Pancreatic Ductal Adenocarcinoma Who Received Neo… Co-author DOI 10.3390/cancers15123231↗
  7. Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metas… Co-author DOI 10.1007/s00428-021-03205-3↗
  8. Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer. Co-author DOI 10.1038/s41588-022-01157-1↗
  9. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). Co-author DOI 10.1093/bjs/znac350↗
  10. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Co-author DOI 10.1136/gutjnl-2020-320726↗
  11. Tumor-insular Complex in Neoadjuvant Treated Pancreatic Ductal Adenocarcinoma Is Associated With Higher Residual Tumor. Last author DOI 10.1097/pas.0000000000001454↗
  12. Pathology of Treated Pancreatic Ductal Adenocarcinoma and Its Clinical Implications. Co-author DOI 10.5858/arpa.2019-0477-ra↗
  13. Residual Tumor Index: A Prognostically Significant Pathologic Parameter in Neoadjuvant-treated Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/pas.0000000000001144↗
  14. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-17-3668↗
  15. Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy. Co-author DOI 10.1097/pas.0000000000000887↗
  16. Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. Co-author DOI 10.1158/0008-5472.can-16-1986↗
  17. Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors. Co-author DOI 10.1158/1078-0432.ccr-15-2780↗
  18. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. Co-author DOI 10.1371/journal.pone.0156910↗
  19. Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype. Co-author DOI 10.1038/labinvest.2014.143↗
  20. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Co-author DOI 10.1245/s10434-014-4192-6↗
  21. The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adeno… Co-author DOI 10.1245/s10434-014-4241-1↗
  22. Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Co-author DOI 10.1088/1478-3975/11/6/065002↗
  23. Extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery. Co-author DOI 10.1158/1078-0432.ccr-14-0970↗
  24. Transport properties of pancreatic cancer describe gemcitabine delivery and response. Co-author DOI 10.1172/jci73455↗
  25. A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Co-author DOI 10.1053/j.gastro.2013.08.018↗
  26. Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal… Co-author DOI 10.1111/his.12234↗
  27. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcom… Co-author DOI 10.1002/cncr.26651↗
  28. Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreat… Co-author DOI 10.1097/pas.0b013e318240c1c0↗
  29. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/pas.0b013e31824104c5↗
  30. Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-12-0223↗

Closest collaborators

The 25 strongest of 129 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huamin Wang · 22 shared papers, 2012–2024 · strength 1.52
  2. Matthew H. G. Katz · 19 shared papers, 2012–2024 · strength 1.22
  3. Robert A. Wolff · 14 shared papers, 2012–2024 · strength 1.01
  4. Hua Wang · 10 shared papers, 2012–2024 · strength 0.97
  5. Eugene Jon Koay · 8 shared papers, 2014–2024 · strength 0.79
  6. Anirban Maitra · 7 shared papers, 2014–2024 · strength 0.77
  7. Michael P. Kim · 6 shared papers, 2015–2024 · strength 0.74
  8. Jeffrey E. Lee · 12 shared papers, 2012–2023 · strength 0.66
  9. Dan Zhao · 4 shared papers, 2023–2024 · strength 0.63
  10. Naruhiko Ikoma · 4 shared papers, 2023–2024 · strength 0.63
  11. Laura R. Prakash · 4 shared papers, 2023–2024 · strength 0.63
  12. Ching-Wei David Tzeng · 4 shared papers, 2023–2024 · strength 0.63
  13. Jason B. Fleming · 16 shared papers, 2012–2018 · strength 0.62
  14. Volkan N. Adsay · 4 shared papers, 2021–2024 · strength 0.48
  15. Gauri Rajani Varadhachary · 10 shared papers, 2012–2018 · strength 0.38
  16. William G. Hawkins · 3 shared papers, 2018–2023 · strength 0.34
  17. Claudio Luchini · 3 shared papers, 2021–2022 · strength 0.34
  18. Lodewijk A.A. Brosens · 3 shared papers, 2021–2022 · strength 0.34
  19. Yi Tat Tong · 2 shared papers, 2023–2024 · strength 0.33
  20. Mehran Taherian · 2 shared papers, 2023–2024 · strength 0.32
  21. Ya’an Kang · 7 shared papers, 2014–2018 · strength 0.29
  22. Olca Baştürk · 2 shared papers, 2022–2024 · strength 0.25
  23. Boris V. Janssen · 2 shared papers, 2022–2024 · strength 0.25
  24. Angela S. Y. Chou · 2 shared papers, 2022–2024 · strength 0.25
  25. Seung‐Mo Hong · 2 shared papers, 2022–2024 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.